Biological therapies for cancer involve the use of living organisms – naturally occurring in the body or laboratory-produced, man-made versions – to improve the body’s natural defenses and its ability to fight cancer. Unlike chemotherapy, which directly attacks the cancer cells, biologic therapy works along with the immune system to fight cancer.
The research and development on biologics to fight cancer has gained much momentum in recent years, mainly owing to the rising prevalence of different types of cancers around the world and growing demand for cost-effective biological therapies. According to the World Health Organization, cancers are among the leading causes of mortality worldwide, with 8.2 million cancer-related deaths in 2012 alone, and 14 million new cases registered that year. Data by WHO reveals that the number of new cancer cases is projected to increase by around 70% over the next two decades.
While early detection is the best way to reduce cancer mortality, adequate and effective treatment plays a major role in fighting the fatal disease.
The biological in oncology market is estimated to reach US$287,139.7 million by 2020, according to a report by Transparency Market Research. Discussed below are the primary factors fueling and restricting the biologicals in cancer therapy market.
Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2310
Availability of Major Biologicals in Oncology Driving Growth
The TMR report states that there are more than 880 companies presently involved in the development of approximately 1,500 drugs to treat 132 different types of cancer. Companies and institutes such as Hadassah University Hospital, Prometheus Therapeutics and Diagnostics, Astex Therapeutics, Rui Jin Hospital, Merck and Company, Immunovative Therapies, National Institute of Mental Health, NewLink Genetics Corporations, Peking University People’s Hospital, F. Hoffmann-La Roche, Ltd., The University of Bologna Medical School, and Northwest Biotherapeutics have been involved in clinical trials aimed at developing cost-effective and commercially-viable biologicals.
The major types of biologics aimed at cancer treatment include cytokine therapy, monoclonal antibodies, RNA oligonucleotide therapy, oncolytic virus therapy, DNA oligonucleotide therapy, gene therapy, adoptive T-cell therapy, and vaccine therapy.
Monoclonal antibodies (MAbs) are laboratory-produced antibodies. While some MAbs stimulate an immune response to destroy cancer cells, there are some that interfere with protein action stimulating tumor growth. Cytokines are signaling proteins produced by white blood cells and they help in mediating and regulating inflammation, immune responses, and the formation of new blood cells. Vaccine therapy involves the use of vaccines to treat cancers that have already developed instead of preventing them in the first place. Oncolytic virus therapy, an experimental biological therapy, involves direct destruction of cancer cells. Gene therapy is another experimental treatment that attempts to introduce genetic material into living cells to target cancer cells, prevent their growth, or destroy them.
Side Effects of Biologic Therapies in Oncology Restricting Large-scale Adoption
Despite the fact that many biologic therapies use naturally-occurring substances, side effects may occur in the event of increased production of these substances.
The side effects associated with various biological cancer therapies differ by type of treatment. The most common ones, however, are swelling, pain, redness, soreness, rash, and itchiness at the site of injection or infusion. Other common side effects also include flu-like symptoms such as chills, fever, nausea/vomiting, body aches, fatigue, and loss of appetite.
Some of the less common yet more serious side effects of biological cancer therapy are breathing difficulties, heightened or lowered blood pressure, or severe to fatal hypersensitivity reactions.
It is the fear of the side effects of biological drugs treatment that acts as the major deterrent for the market.
The field of biologic therapies in oncology is still relatively new and research organizations, drug companies, and health and medical science institutes are working tirelessly to minimize the side effects and improve the efficacy of these experimental therapies.
Browse Full Global Biologicals In Oncology Market Report With Complete TOC @ http://www.transparencymarketresearch.com/biologicals-oncology-market.html
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY – 12207